行情

AIM

AIM

AIM ImmunoTech Inc
AMEX

实时行情|Nasdaq Last Sale

2.070
+0.090
+4.55%
已收盘, 19:05 09/21 EDT
开盘
2.000
昨收
1.980
最高
2.080
最低
1.950
成交量
262.53万
成交额
--
52周最高
3.060
52周最低
1.650
市值
9,904.66万
市盈率(TTM)
-5.4146
分时
5日
1月
3月
1年
5年
BRIEF-AIM ImmunoTech Says Ellen Lintal To Retire As CFO
reuters.com · 10小时前
AIM ImmunoTech 对 PCCD 患者的 Ampligen 试验获得 FDA 的积极响应
Benzinga · 13小时前
BRIEF-AIM Immunotech Announces Positive Progress On Requested FDA Meeting For Proposed Ampligen Clinical Trial In Post-Covid-19 Cognitive Dysfunction
reuters.com · 20小时前
AIM ImmunoTech 表示 FDA 会议请求已被认为足以转移到 FDA 的神经病学部门
AIM ImmunoTech Inc. (NYSE:AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion
Benzinga · 21小时前
AIM ImmunoTech 宣布就 COVID-19后认知功能障碍的拟议 Ampligen 临床试验要求的 FDA 会议取得积极进展
OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as ...
GlobeNewswire · 21小时前
AIM ImmunoTech FDA 会议要求将 Ampligen 研究转移到神经科;股价在响铃前上涨
MT Newswires · 1天前
Brief-Aim Immunotech 使用其药物 Ampligen 提供了其未决的 2A 期人类挑战试验的最新信息
reuters.com · 1天前
AIM ImmunoTech 使用其药物 Ampligen 提供了其未决的 2a 期人类挑战试验的最新信息
AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold virus) an...
GlobeNewswire · 1天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AIM最新的财务预测,通过AIM每股收益,每股净资产,每股现金流等数据分析AIM ImmunoTech Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AIM价格均价为6.67,最高价位8.50,最低价为5.00。
EPS
机构持股
总机构数: 15
机构持股: 9.35万
持股比例: 0.20%
总股本: 4,784.86万
类型机构数股数
增持
6
31
建仓
4
7.09万
减持
2
2,899
平仓
7
1.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.43%
制药与医学研究
+0.74%
高管信息
Chairman/Director
William Mitchell
President/Chief Executive Officer/Vice Chairman/General Counsel/Secretary/Director
Thomas Equels
Chief Financial Officer
Ellen Lintal
Chief Operating Officer/General Counsel/Secretary
Peter Rodino
Senior Vice President
Wayne Springate
Chief Scientific Officer
David Strayer
Director
Stewart Appelrouth
暂无数据
AIM 简况
AIM ImmunoTech Inc. is a specialty pharmaceutical company. The Company focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is a drug which is also known as a new molecular entity that contains an active moiety. It is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen (rintatolimod), It is a drug of macromolecular RNA (ribonucleic acid) molecules, It is a sterile solution indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

微牛提供AIM ImmunoTech Inc(AMEX-AIM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AIM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AIM股票基本功能。